Amicus Therapeutics, Inc. (AM6.F)

9.65 +0.15 (+1.58%) As of 08:31AM CEST. Market open.

Amicus Therapeutics, Inc.

47 Hulfish Street
Princeton, NJ 08542
United States
609 662 2000
https://amicusrx.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 517

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Bradley L. Campbell M.B.A.	CEO, President & Director	1.35M	1.22M	1976
Mr. Simon Nicolas Reade Harford	Chief Financial Officer	537.26k	N/A	1960
Ms. Ellen S. Rosenberg	Chief Legal Officer & Corporate Secretary	840.31k	290.46k	1964
Mr. David M. Clark	Chief People Officer	796.2k	N/A	1976
Dr. Jeffrey P. Castelli Ph.D.	Chief Development Officer	802.41k	N/A	1972
Ms. Samantha Prout	Chief Accounting Officer & Controller	N/A	N/A	1978
Dr. Jill Weimer Ph.D.	Chief Science Officer	N/A	N/A	N/A
Andrew Faughnan	Senior Director of Investor Relations	N/A	N/A	N/A
Mr. Patrik S. Florencio Esq.	Global Chief Compliance & Risk Officer	N/A	N/A	N/A
Ms. Diana Moore	Head of Global Corporate Communications	N/A	N/A	N/A

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.

Corporate Governance

Amicus Therapeutics, Inc.’s ISS Governance QualityScore as of April 29, 2024 is 6. The pillar scores are Audit: 8; Board: 5; Shareholder Rights: 7; Compensation: 5.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.